seekingalpha.com /5 days ago

Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript

Read source
investinglive.com /1 month ago

INmune Bio Establishes Global Commercialization Framework for Ebstrocelâ„¢ Through Strategic Agreement with Uniphar

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into...

Read source
seekingalpha.com /1 month ago

Primary Markets Group September 2026 U.S. IPO Update

Read source
pharmexec.com /2 days ago

<![CDATA[Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks]]>

Read source
seekingalpha.com /1 month ago

Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Sc...

Read source
seekingalpha.com /1 week ago

Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Sec...

Read source
fool.com /2 weeks ago

Inspire (INSP) Q3 2026 Earnings Call Transcript

Reimbursement headwinds cut Q3 revenue, but 2027 outlook improves.

Read source
fool.com /2 weeks ago

Inspired (INSE) Q3 2026 Earnings Call Transcript

Regulatory headwinds hit results, but digital growth lifted margins.

Read source
seekingalpha.com /1 month ago

Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript

Read source
seekingalpha.com /2 weeks ago

InflaRx N.V. (IFRX) Analyst/Investor Day Transcript

Read source
seekingalpha.com /1 month ago

Trinity Capital commits $20M to respiratory care firm ABM

Read source
pharmexec.com /1 month ago

<![CDATA[InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly]]>

Read source
seekingalpha.com /1 week ago

DocMorris AG (ZRSEF) Analyst/Investor Day - Slideshow

Read source
pharmexec.com /1 week ago

<![CDATA[argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities ]]>

Read source
prweb.com /2 weeks ago

INVI MindHealth Collaborates with Baylor College of Medicine and The Menninger Clinic to Assess Objective Biomarkers for...

Participating sites will use INVI's platform to capture and integrate longitudinal data across emerging mental health interventions HOUSTON, Nov. 2, 2026 /PRNewswire-PRWeb/ -- INVI...

Read source
seekingalpha.com /1 day ago

Immatics: A Slow Event Clock And A Proven Market Make The SUPRAME Setup Better Than It Looks

Read source
seekingalpha.com /1 week ago

Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Sec...

Read source
seekingalpha.com /1 month ago

Merck KGaA to buy Silence Therapeutics in all-cash deal

Read source
pharmexec.com /2 days ago

<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>

Read source
qchron.com /1 month ago

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWall...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.